title: Translocation t(7;11)(P15;P15) in a patient with therapy-related acute myeloid leukemia following bimolane and ICRF-154 treatment for psoriasis.
abstract: The t(7;11)(p15;p15) translocation is an uncommon balanced aberration which has been found predominantly in Orientals, frequently presenting as de novo acute myeloid leukemia (AML) and occasionally as chronic myeloid leukemia in blastic crisis. This paper reports the first case of therapy-related AML (t-AML) with t(7;11). The patient was a 36-year-old Chinese man with a longstanding psoriasis for which he had received bimolane and ICRF-154 therapy. His cytology and cytochemistry were compatible with M2 subtype of AML. He achieved a complete remission after two courses of HA regimen (homoharringtonine and Ara-c). Six months later, he relapsed and died of overwhelming infection after 3 months. Chromosome analysis on bone marrow cells using short-term culture and R-banding at presentation revealed his karyotype to be 46,XY,t(7;11)(p15;p15)/ 46,XY,t(7;11)(p15;p15),del(12)(p12)/ 46,XY. This case implies: (1) dioxopiperazine derivatives can induce AML with t(7;11) in addition to inducing AML with t(15;17) or t(8;21); (2) t(7;11) may be found not only in de novo AML, but also in t-AML. Chromosomal translocation t(7;11) should be added to t(8;21), t(15;17) and inv(16) as favourable cytogenetic abnormalities associated with t-AML.
authors.affiliation: Leukemia Research Unit, Jiangsu Institute of Hematology, Suzhou, People's Republic of China.
authors.forename: Y
authors.initials: Y
authors.lastname: Xue
authors.forename: Y
authors.initials: Y
authors.lastname: Guo
authors.forename: X
authors.initials: X
authors.lastname: Xie
mesh_terms: D000208:Acute Disease; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002880:Chromosomes, Human, Pair 11; D002897:Chromosomes, Human, Pair 7; D006801:Humans; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000139:chemically induced / Q000235:genetics*; D008297:Male; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000235:genetics*; D011565:Psoriasis / Q000188:drug therapy*; D011929:Razoxane / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014178:Translocation, Genetic
chemical_list: D000970:Antineoplastic Agents; C031186:bimolane; D011929:Razoxane; C000283:1,2-bis(3,5-dioxopiperazin-1-yl)ethane